Subscribe To

Price Alert Latest News Economic Calendar News

NAUT / Jim Cramer considers the investment cases for Nautilus Biotechnology and Cyxtera Technologies

On Friday's episode of "Mad Money," host Jim Cramer reviewed the investment cases for Nautilus Biotechnology and Cyxtera Technologies, two companies that viewers had previously called about in search of advice. Read More

Demo Live Account See Partner Details

Content Topics

Cramer

Considers

Investment

Cases

Nautilus

Biotechnology

Cyxtera

Technologies

Stock

NAUT

Posted: Jan 21 2022, 20:11

Author Name: CNBC Television

NAUT News

By Seeking Alpha
October 31, 2023

Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Suj

By GlobeNewsWire
October 11, 2023

Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule prot

By Seeking Alpha
August 2, 2023

Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor

By GlobeNewsWire
July 11, 2023

Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023

SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule prot

By GlobeNewsWire
May 24, 2023

Nautilus Biotechnology to Participate in Upcoming June Investor Conferences

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule prote

By GlobeNewsWire
March 23, 2023

Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule pro

By PennyStocks
March 17, 2023

3 Penny Stocks Under $3 To Watch In March

Penny stocks to watch right now. The post 3 Penny Stocks Under $3 To Watch In March appeared first on Penny Stocks to Buy, Picks, News and Information

By Seeking Alpha
February 25, 2023

Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Sujal Patel - Co-Founde

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.